Author Archive | James A. Mitchell

We are pleased to share with you the message just received, ranking Mitchell IP Law among the best law firms: “Congratulations again on your law firm’s ranking in the 2016 Edition of “Best Law Firms” by U.S News & World Report and Best Lawyers.” We would like to thank all of you, our friends and clients, […]

Those engaged in the generic drug business are well familiar with the long term efforts by the Federal Trade Commission to obtain a significant anti-trust judgement in a so-called “Pay to Delay” action.  Cephalon Inc. agreed Thursday to pay $1.2 billion to settle a long-running antitrust suit.  Cephalon was accused of paying generic drug makers […]

Kyle Bass, founder of hedge fund Hayman Capital Management, has added two Shire PLC drugs to his list of pharma patent targets. An organization tied to Bass has challenged the patents in an inter partes review proceeding in the United States Patent Office. This procedure was recently made available under the America Invents Act (AIA). Hayman […]

MITCHELL HONORED BY PEERS AS AMONG BEST LAWYERS IN AMERICA We are pleased to announce that James A. Mitchell has again been selected by his peers for inclusion in the 21st Edition of Best Lawyers in America in the practice areas of: Litigation – Intellectual Property Law, And Patent and Trademark Law.  This makes more than […]

When was your company employee intellectual property agreement written?  When was it last reviewed?  Does it deal with confidential information leaks occasioned by an employee’s use of personal computers for company business?  We recommend including a provision such a All work done by Employee which relates to the activities of the Company shall be done […]

The U.S. District Court for the Eastern District of Virginia invalidated Pfizer’s method-of-use patent on its Celebrex painkiller. The basic chemical patent on Clebrex will lapse May 30, 2014.  Pfizer hoped the method-of-use patent would allow it to maintain market exclusivity on Celebrex through Dec. 2, 2015. Pfizer currently enjoys $3 billion in annual sales from […]

Mitchell Intellectual Law is pleased to announce that its hourly rates and fixed fees will remain unchanged for 2014, with two minor exceptions: The fee for paying the patent issue fee, docketing for maintenance fees and reviewing the issued patent for accuracy will be reduced. The fee for reviewing the application at the time of Notice […]

Mitchell IP law is pleased to welcome Bruce M. Kanuch into the firm. Bruce holds a Bachelor of Science degree from Purdue University, his Juris Doctorate Law degree from the University of Minnesota. Bruce specializes in patent prosecution, trademark and copyright law and related contract drafting and negotiation. He was in house patent counsel and patent litigation […]

Mitchell IP Law founder James Mitchell was recently asked by WOTV to comment on a “click to agree” contract used by a vendor. A “click to agree” contract is the type we typically find when doing business on the web or downloading software to our computers. Most people simply “click to agree,” without reading these […]

THINGS YOU NEED TO KNOW ABOUT PROVISIONAL PATENT APPLICATION CONVERSION DEADLINES To preserve the benefit of your provisional patent application filing date, you will need to convert the provisional application to a US and/or PCT non-provisional patent application within one year of your provisional application filing date. Failure to do so may result in forfeiture […]